BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22829569)

  • 1. Uterine leiomyosarcoma in asian patients: validation of the revised Federation of gynecology and obstetrics staging system and identification of prognostic classifiers.
    Tan PS; Koh E; Pang C; Ong WS; Ngo L; Soh LT; Quek R; Chay WY; Ho TH; Tay SK; Chew SH; Lim-Tan SK; Khoo-Tan H; Lim SL; Busmanis I; Goh LK; Chia YN; Chia WK; Lim T
    Oncologist; 2012; 17(10):1286-93. PubMed ID: 22829569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
    Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
    Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIGO staging for uterine sarcomas: can the revised 2008 staging system predict survival outcome better?
    Yim GW; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2014 May; 55(3):563-9. PubMed ID: 24719120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
    Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
    Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.
    Zivanovic O; Leitao MM; Iasonos A; Jacks LM; Zhou Q; Abu-Rustum NR; Soslow RA; Juretzka MM; Chi DS; Barakat RR; Brennan MF; Hensley ML
    J Clin Oncol; 2009 Apr; 27(12):2066-72. PubMed ID: 19255317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system.
    Seward S; Ali-Fehmi R; Munkarah AR; Semaan A; Al-Wahab ZR; Elshaikh MA; Cote ML; Morris RT; Bandyopadhyay S
    Int J Gynecol Cancer; 2012 Mar; 22(3):452-6. PubMed ID: 22274544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
    Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
    Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases.
    Lim D; Wang WL; Lee CH; Dodge T; Gilks B; Oliva E
    Gynecol Oncol; 2013 Feb; 128(2):322-6. PubMed ID: 23153591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
    Kapp DS; Shin JY; Chan JK
    Cancer; 2008 Feb; 112(4):820-30. PubMed ID: 18189292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?
    Pradhan TS; Stevens EE; Ablavsky M; Salame G; Lee YC; Abulafia O
    Gynecol Oncol; 2011 Nov; 123(2):221-4. PubMed ID: 21889193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Apr; 35(4):2229-34. PubMed ID: 25862883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in early-stage leiomyosarcoma of the uterus.
    Pelmus M; Penault-Llorca F; Guillou L; Collin F; Bertrand G; Trassard M; Leroux A; Floquet A; Stoeckle E; Thomas L; MacGrogan G
    Int J Gynecol Cancer; 2009 Apr; 19(3):385-90. PubMed ID: 19407564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
    Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
    Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study.
    Zeng J; Qu P; Hu Y; Sun P; Qi J; Zhao G; Gao Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19714. PubMed ID: 32311956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer.
    Gravbrot N; Weil CR; DeCesaris CM; Gaffney DK; Suneja G; Burt LM
    Eur J Cancer; 2024 Apr; 201():113913. PubMed ID: 38377777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
    D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
    Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
    Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
    Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
    Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
    Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
    Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.